April 27, 2024
Bio
Medytox steps up R&D efforts with new center
[THE INVESTOR] Korea’s botulinum toxin maker Medytox said on Aug. 23 it has opened a research center to push its drug development beyond facial injectables.
The Medytox Research & Development Center in Gwanggyo, Gyeonggi Province, will serve as the science hub for the company and help it to build a specialty pharmaceutical pipeline.
 |
“The Gwanggyo R&D center is expected to bring us tangible results as the facility will enable Medytox’s talented researchers to collaborate and integrate drug development projects,” the firm’s CEO Jung Hyun-ho said.
Medytox, which has been focusing on anti-wrinkle treatment and dermal fillers, seeks to diversify its product portfolio to antibody treatments, oncology drugs as well as therapies for obesity and arthritis.
The facility -- a 9,322-square-foot R&D center will become home to 200 scientists as the company plans to double the number of researchers from existing 100 people.
By Park Han-na (hnpark@heraldcorp.com)
